CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference – Yahoo Finance
Posted: November 20, 2020 at 5:58 pm
Benzinga
Who would have thought 2020 would be the dawn of a new era in electric vehicle stocks. Though many of these companies have been on the market in one shape or form for years, most have traded as penny stocks. Tesla Inc (NASDAQ: TSLA), which was always the top dog in the industry, now finds itself with a number of major competitors.There's no denying that FOMO (fear of missing out) has driven short-term trends in these lesser-known names, and those who invested early are now reaping the benefits.Before we continue, we need to acknowledge that these stocks carry huge amounts of risk. The EV stocks detailed below are all volatile like penny stocks. So if you are looking for ways to trade these names or make money with penny stocks, it's important to control your downside.All that being said, a number of new EV stocks have also helped fuel demand. Let's say you decided that after the March sell-off this year to invest some money into electric vehicle penny stocks. What would that look like right now if you were to take $500 at that time and throw it blindly into some of these names?Kandi Technologies Group, Inc. (NASDAQ: KNDI)Kandi Technologies is one of the newer names in the space. In 2013, the company and Geely Group, a Chinese automaker, jointly invested in the establishment of Fengsheng Automotive Technology Group Co., Ltd. in order to develop, manufacture and sell pure EV products. Earlier this year, Fengsheng introduced its first pure electric SUV, the Maple 30x.Fast-forward to today and Kandi has established dealer partnerships for the retail launch of two "affordable EV models"- K23 and K27. Shares of KNDI have rallied almost 180% in the last two weeks, nearly getting back to the all-time high of $17.40 from July 30.A $500 investment in Kandi in mid-March would've gotten someone around 230 shares. At today's price, that position would be worth around $3,300. That's a 560% return.ElectraMeccanica Vehicles Corp (NASDAQ: SOLO)ElectraMeccanica's flagship is a single-passenger EV dubbed "SOLO". The company has been working toward commercialization and building its U.S. footprint, with its first round of new retail locations just announced at the end of October and the initial shipment of SOLO EV's just arriving in North America.With commercial launch imminent and momentum as a backdrop, SOLO shares have surged in recent weeks. In a July interview with Benzinga, ElectraMeccanica CEO Paul Rivera said, "We are not trying to compete with Tesla... When you're driving this car, it's just you, and you're focused on the road."With SOLO shares trading around $0.90 in mid-March, a $500 position would be somewhere in the ballpark of 555 shares. As of Thursday, the former penny stock reached a high of $9.74 making that position worth about $5,405, a 900% gain.Blink Charging Co. (NASDAQ: BLNK)Another one of the "pick and shovel" EV stocks is Blink Charging. The company continues gaining exposure as its charging stations remain a hot topic among traders and customers alike. Not only has Blink focused on expanding its charging footprint, but the company has also benefitted from other industry news. Apple Inc (NASDAQ: AAPL) for example, announced earlier this year that its Apple Maps would include EV charge routing. According to Blink, that will include its charging stations. Last week, Blink introduced a cable management solution for new and existing EV charger locations.BLNK reached a new all-time high Thursday, breaking $19 for the first time. A $500 position in BLNK around mid-March would equate to roughly 312 shares at $1.60. At today's price that position is worth over $5,720 or an over 1,000% gain.Ayro Inc. (NASDAQ: AYRO)Ayro Inc. initially focused on manufacturing short-haul electric vehicles, such as things that drive around college campuses and office complexes. But the company's recent deal with Karma Automotive forms a partnership that includes a plan to produce more than 20,000 light-duty trucks over the next three years. It's also reportedly worth as much as $300 million. While AYRO is still one of the lower-priced EV stocks, shares have been equally explosive. Prior to its merger with DropCar, shares were trading around $0.40 in mid-March. A $500 position was equal to roughly 1,250 shares of DCAR - now AYRO. At this week's current levels above $6, that position is worth right around $7,700.Green Power Motors (NASDAQ: GP)Green Power was originally listed on the TSX Venture market and traded in the U.S. on the OTCQX Market under the symbol GPVRF. After filing for a $35 million IPO on the Nasdaq, Green Power began trading under GP, the symbol it's known for today. The company manufactures electric buses, cargo delivery vehicles, shuttles, and transit vehicles. Green Power recently closed a deal for six electric school buses that were sold to Thermalito Union Elementary School District through Greenpower's national distributor, Creative Bus Sales.While GP reached of $23.45 earlier this year, the former penny stock currently trades around $19. Back in mid-March when Green Power was still on the OTCQX, the penny stock was worth around $1.05 meaning a $500 position was equal to about 476 shares. As of recent levels of $19, that position is now 1,700% higher valued at around $9,000.Workhorse Group (NASDAQ: WKHS)Who could forget Workhorse Group? It was one of the electric vehicle penny stocks originally brought to life by a Trump Tweet last summer. The company specializes in medium-duty trucks with powertrain components under the Workhorse chassis brand. Most recently, WKHS caught some momentum after receiving a purchase order for 500 all-electric C-1000 delivery vehicles from Pritchard Companies. Some of the momentum had been stifled following news that Ford Motor Company (NYSE: F) would be rolling out its own electric cargo vehicle.Needless to say, it hasn't been a bad year for the former penny stock. In mid-March, shares were trading around $1.50. At its peak, WKHS reached highs of $30.99. Currently, the EV stock sits around $22.78 a share. That means a $500 position in March (roughly 333 shares) is now worth over $7,580 or an over 1,400% gain.Nio Inc. (NYSE: NIO)Nio isn't the new kid on the block anymore. Last year NIO became a penny stock, at one point trading as low as $1.19. Though it didn't experience a massive sell-off like most of the market did in the first quarter, shares of NIO stock were hovering around $2.30 in mid-March. But in light of the company's recent earnings beat, NIO is at $48, knocking on the door of all-time highs. A $500 position in Mid-March would equate to about 217 shares of NIO. Today that would be worth $10,500, equating to a gain of over 2,000%. Neither the author of this post nor Pennystocks.com have a position or financial relationship with any of the stocks mentioned above. See more from Benzinga * Click here for options trades from Benzinga * Cannabis Stock Gainers And Losers From November 19, 2020 * Bitcoin, Ethereum & Chainlink - American Wrap: 11/19/2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Go here to see the original:
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Yahoo Finance
- Bear of the Day: CRISPR Therapeutics (CRSP) - Yahoo Finance - February 14th, 2021
- Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day - Yahoo Finance - February 14th, 2021
- CRISPR Technology Market hits at $3.94 Bn by 2028 with Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT) - The... - February 14th, 2021
- AbbVie and Caribou partner on CAR-T cell therapy development - BioPharma-Reporter.com - February 14th, 2021
- CRISPR Treatment Offers The Potential To Live Forever - ValueWalk - February 14th, 2021
- Australia Gene Editing Market to Garner Astonishing CAGR by 2028 with Top Key Players: CRISPR Therapeutics, Thermo Fisher Scientific, GenScript... - February 14th, 2021
- CRISPR Offers the Potential to Live Forever, But to What End? - Entrepreneur - February 11th, 2021
- Global CRISPR Gene Editing Market (2020 to 2030) - Focus on Products, Applications, End-users, Country Data and Competitive Landscape -... - February 9th, 2021
- Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire - February 9th, 2021
- CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day - Yahoo Finance - February 9th, 2021
- CRISPR and CAS Gene Market Competitive Insights With Global Outlook 2020-2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas... - February 9th, 2021
- Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and... - February 1st, 2021
- Massive Growth of Gene Editing Tools Market 2021 | Size, Demand, Opportunities & Forecast To 2027 | Thermofisher Scientific, CRISPR Therapeutics,... - February 1st, 2021
- Mammoth Biosciences teams with Agilent to deliver CRISPR-based coronavirus tests - FierceBiotech - February 1st, 2021
- Inherited blindness has a new cure, thanks to CRISPR - Genetic Literacy Project - February 1st, 2021
- An Alternate Approach To Stopping Mosquitoes That Spread Zika - Using CRISPR To Make Them Resistant To Carrying It - Science 2.0 - February 1st, 2021
- CRISPR and CAS Gene Market to Score Past US$ 7603.8 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - February 1st, 2021
- Diseases once thought incurable are now on the cusp of treatments. It's because of CRISPR. Here's a primer - Genetic Literacy Project - February 1st, 2021
- Experts Predict the Hottest Life Science Tech in 2021 and Beyond - The Scientist - February 1st, 2021
- Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now - Motley Fool - February 1st, 2021
- Bystander Killing Could Be Key Factor in CAR-T Success in Non-Hodgkin Lymphoma - Cancer Therapy Advisor - February 1st, 2021
- Study on plant genome editing with new variant of CRISPR-Cas9 - hortidaily.com - January 27th, 2021
- Using CRISPR Genetic Technology to Catch Cancer in the Act - SciTechDaily - January 27th, 2021
- Two Gene Therapies Fix Fault in Sickle Cell Disease and -thalassemia - MD Magazine - January 27th, 2021
- Comprehensive Report on Crispr And Crispr-Associated (Cas) Genes Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 | Intellia... - January 27th, 2021
- Natural CRISPR's Safety Feature Could Become Genetic Dimmer Switch - Genetic Engineering & Biotechnology News - January 23rd, 2021
- CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why - Yahoo Finance - January 23rd, 2021
- The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics - Yahoo Finance - January 23rd, 2021
- Investors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares Three Years Ago Are Now Up 411% - Simply Wall St - January 23rd, 2021
- We may have a CRISPR cure for red blood diseases sickle cell anemia and beta thalassemia - Genetic Literacy Project - January 23rd, 2021
- The ARKG ETF: Join the Genomics Revolution - ETF Trends - January 23rd, 2021
- Gene-edited crops are now a reality but will the public be on board? - The Conversation UK - January 23rd, 2021
- 'Incredible' gene-editing result in mice inspires plans to treat premature-aging syndrome in children - Science Magazine - January 9th, 2021
- CRISPR Therapeutics Is Still Looking Strong - RealMoney - RealMoney - January 9th, 2021
- Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change - Market is Expected to Recover to Reach $1.55 Billion in 2023 - Forecast to... - January 9th, 2021
- What is the Market's View on Crispr Therapeutics AG (CRSP) Stock's Price and Volume Trends - InvestorsObserver - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- CRISPR-based strategies in infectious disease diagnosis and therapy - DocWire News - January 9th, 2021
- Plant Breeding And CRISPR Plants Market Is Expected To Reach USD 21.78 Billion By 2027 | Top Companies- Bayer AG, KWS SAAT SE & Co. KGaA, DuPont,... - January 9th, 2021
- Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver - January 9th, 2021
- CRISPR and CAS Gene Market 2021-2028 shooting revenue at US$ 7,603.8 Million with CRISPR Therapeutics, Mirus Bio, Caribou Biosciences, Editas... - January 9th, 2021
- The 221b Foundation Establishes Coalition to Control the Spread of COVID-19 in Nepal - Business Wire - January 9th, 2021
- Strategies and applications for CRISPRko, RNAi and beyond - SelectScience - January 9th, 2021
- TRIM26 is a critical host factor for HCV replication and contributes to host tropism - Science Advances - January 9th, 2021
- Four Predictions for the Future of Food in 2021 - The Spoon - January 9th, 2021
- Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today - The Motley Fool - January 2nd, 2021
- Should Crispr Therapeutics AG (CRSP) be in Your Portfolio? - InvestorsObserver - January 2nd, 2021
- Can CRISPR Save Florida Citrus? - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - January 2nd, 2021
- 2020: The year science took centre-stage - The Hindu - January 2nd, 2021
- 2020 was a tough year, but there is a silver lining - Boston Herald - January 2nd, 2021
- Pairing CRISPR with a smartphone camera, this COVID-19 test finds results in 30 minutes - FierceBiotech - December 12th, 2020
- New CRISPR-based COVID-19 test uses smartphone cameras to spot virus RNA - University of California - December 12th, 2020
- Is CRISPR Therapeutics Heading for $170? - The Motley Fool - December 12th, 2020
- Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment... - December 12th, 2020
- De-extinction: Why CRISPR gene editing might be the most revolutionary development in science ever - Genetic Literacy Project - December 12th, 2020
- How CRISPR could help us discover and treat rare cancers - ZME Science - December 12th, 2020
- ASH: CRISPR-Cas9 Gene Editing Promising in TDT, SCD - HealthDay News - December 12th, 2020
- Kevin Davies' 'Editing Humanity' explores the CRISPR revolution and the ethical dilemmas that await us - Genetic Literacy Project - December 12th, 2020
- ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more - PMLiVE - December 12th, 2020
- CiBER-seq dissects genetic networks by quantitative CRISPRi profiling of expression phenotypes - Science Magazine - December 12th, 2020
- CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Yahoo Finance - November 30th, 2020
- Global $6.7 Billion CRISPR Technology Market Opportunities to 2030: Cas9 And gRNA, Design Tool, Plasmid and Vector, Other Delivery System Products -... - November 30th, 2020
- CRISPR Therapeutics AG [CRSP] Revenue clocked in at $77.40 million, up 99.57% YTD: Whats Next? - The DBT News - November 30th, 2020
- Crispr And Crispr-Associated (Cas) Genes Market trends, Forecast Analysis, Key segmentation by type and application to 2026 - Cheshire Media - November 30th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Insights with Global Outlook 2020-2026| Caribou Biosciences, Addgene, CRISPR THERAPEUTICS... - November 30th, 2020
- CRISPR Genome Editing Market Statistics and Research Analysis Released in Latest Industry Report 2020 | Coronavirus-COVID19 Impact Analysis With Top... - November 30th, 2020
- CRISPR Genome Editing Market to Exhibit Impressive Growth of CAGR during the pe - News by aeresearch - November 30th, 2020
- Autism genes affect development of neurons and glia - Spectrum - November 30th, 2020
- CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy - Science Advances - November 20th, 2020
- Heres Why You Should Stay Invested In CRISPR Stock Despite The Recent 3x Rally - Forbes - November 20th, 2020
- CRISPR for Citrus Greening - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - November 20th, 2020
- Viewpoint: Farming one of the 'most inefficient industries.' The CRISPR revolution could change that - Genetic Literacy Project - November 20th, 2020
- CRISPR-edited bananas immune to killer pathogens advance toward commercialization in Africa - Genetic Literacy Project - November 20th, 2020
- CRISPR Technology Market Forecast To 2026 And COVID-19 Impact Analysis - The Think Curiouser - November 20th, 2020
- Faster, Cheaper, Easier COVID-19 Testing - Powering the New Engineer - University of Florida - November 20th, 2020
- Seeing Real-Time Biological Interactions with Graphene Transistors - Clinical OMICs News - November 20th, 2020
- Crispr Technology Market to 2026: Report on Top Company Players, Industry Insights and Overview - PRnews Leader - November 20th, 2020
- Application and Product Portfolio Analysis During the forecasted period of CRISPR Technology Market - PRnews Leader - November 20th, 2020
- CRISPR Genome Editing Market Research Report- Opportunities & Challenges With Totally Different Segments, Forecast- 2026 - The Think Curiouser - November 3rd, 2020
- Latest News 2020: CRISPR Technology Market by Coronavirus-COVID19 Impact Analysis With Top Manufacturers Analysis | Top Players: Thermo Fisher... - November 3rd, 2020